lecanemab
eisai
['lecanemab']
van dyck defended the clinical meaningfulness of the 0.45 cdr-sb difference in the clarity ad trial favoring lecanemab at #aanam. the 7.5 months of time saved is based on the assumption that the placebo-treatment curves (1) diverge and (2) will continue to diverge. 
Professor of #neurology @uofcincy. Walking the talk: there is no #Parkinsons but people with Parkinson's. Author, #BrainFables.